Pasithea TherapeuticsKTTA
KTTA
About: Pasithea Therapeutics Corp is a biotechnology company. It is focused on the discovery, research, and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers. It leveraging in the fields of neuroscience, translational medicine, and drug development. Its pipeline includes Neurofibromatosis Type 1, Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), and Schizophrenia. Companies pipelines includes PAS-004 (Macrocyclic Small Module[MEK1/2]), PAS-003 (Monoclonal antibody),PAS-001 (Small Module).
Employees: 4
0
Funds holding %
of 7,296 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
50% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 2
14% more funds holding
Funds holding: 7 [Q4 2024] → 8 (+1) [Q1 2025]
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
3.16% less ownership
Funds ownership: 6.08% [Q4 2024] → 2.91% (-3.16%) [Q1 2025]
59% less capital invested
Capital invested by funds: $243K [Q4 2024] → $99.1K (-$144K) [Q1 2025]
Research analyst outlook
We haven’t received any recent analyst ratings for KTTA.
Financial journalist opinion
Based on 3 articles about KTTA published over the past 30 days
Neutral
GlobeNewsWire
4 days ago
Pasithea Therapeutics Appoints Expert in ETS2-driven Inflammatory Disease to Scientific Advisory Board
MIAMI, June 11, 2025 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor, today announced the appointment of Dr. James Lee to its scientific advisory board (SAB) to help guide development of PAS-004 for the treatment of ETS2 pathway inflammatory diseases including inflammatory bowel disease (IBD), ulcerative colitis, Crohn's disease, primary sclerosing cholangitis and ankylosing spondylitis. Dr. Lee is the lead author on a 2024 Nature publication that identified ETS2 as a central regulator of macrophage-driven inflammation in IBD and other indications, and also identified that MEK inhibitors are the drug class that most effectively suppress ETS2-driven inflammation.
Neutral
GlobeNewsWire
1 week ago
Pasithea Therapeutics Presents Updated Interim Data from Ongoing Phase 1 Study of PAS-004 at the ASCO Annual Meeting 2025
PAS-004 shows early signs of efficacy and strong tolerability in Phase 1 cancer trial, with tumor reductions and disease stability in pre-treated patients
Neutral
GlobeNewsWire
3 weeks ago
Pasithea Therapeutics Announces Preclinical Data that Shows PAS-004 Inhibits ETS2 Signaling, a Key Driver of Inflammation in IBD and Other Large Addressable Market Diseases
-- Demonstrates PAS-004's potential as a differentiated MEK inhibitor for immune-mediated inflammatory diseases such as IBD and ankylosing spondylitis – -- Positions PAS-004 for potential expansion beyond MAPK pathway driven tumors into inflammatory diseases – -- PAS-004 outperforms FDA-approved MEK inhibitor selumetinib in targeting ETS2 pathway – -- Study conducted at Francis Crick Institute by lead author of 2024 Nature paper that identified ETS2 as a central regulator of macrophage-driven Inflammation in IBD -- MIAMI, May 20, 2025 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor, today announced new preclinical data demonstrating that PAS-004 provides superior inhibition of ETS2-driven inflammatory responses compared to selumetinib in a human macrophage model of chronic inflammation that mimics the inflammatory milieu seen in inflammatory bowel disease (IBD). This study was conducted at the Francis Crick Institute in London, U.K. by Dr. James Lee, a gastroenterologist and Clinician Scientist Group Leader at the Genetic Mechanisms of Disease Laboratory.
Neutral
GlobeNewsWire
1 month ago
Pasithea Therapeutics Announces Initiation of Phase 1/1B Study of PAS-004 in Adult NF1 Patients and Activation of First Clinical Trial Site
Pasithea begins PAS-004 Phase 1/1b NF1 trial in Australia, with U.S. and S. Korea sites planned. First dosing set for Q2 2025. 48.5% R&D refund expected.
Neutral
GlobeNewsWire
1 month ago
Pasithea Therapeutics Announces Closing of $5 Million Public Offering
Pasithea Therapeutics (Nasdaq: KTTA) closes $5M public offering, adds $1.3M via warrant exercises, funding R&D for PAS-004 and other biotech innovations.
Neutral
GlobeNewsWire
1 month ago
Pasithea Therapeutics Announces Pricing of $5 Million Public Offering
Pasithea Therapeutics (Nasdaq: KTTA) prices $5M public offering to fund clinical trials, R&D, and corporate initiatives; closing expected May 7, 2025.
Positive
Benzinga
1 month ago
Pasithea Therapeutics Drug Shows Tumor Reduction In Pancreatic Cancer, Strong Early Trial Results
Pasithea Therapeutics Corp. KTTA is trading higher in the premarket session on Tuesday with a session volume of 22.14 million compared to the average volume of 2.81 million as per data from Benzinga Pro.
Neutral
GlobeNewsWire
1 month ago
Pasithea Therapeutics Reports Positive Pharmacodynamic Results Demonstrating Robust Target Engagement from its Ongoing Phase 1 Clinical Trial of PAS-004
Pasithea Tx' PAS-004 shows up to 91% pERK inhibition in Phase 1 trial; one pancreatic cancer patient sees 4+ months stable disease and tumor shrinkage.
Neutral
GlobeNewsWire
1 month ago
Pasithea Therapeutics Announces Completion of Enrollment and Initial Dosing of Patients in Cohort 6 from its Phase 1 Trial of PAS-004 in Advanced Cancer Patients
MIAMI, April 29, 2025 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor, for the treatment of neurofibromatosis type 1 (NF1) and other MAPK pathway driven cancer indications, today announced the Company has completed enrollment and initial dosing of three subjects in Cohort 6 with 30 mg capsules of PAS-004. “We are pleased to have recruited, enrolled and commenced dosing of the initial three subjects in Cohort 6 more rapidly than anticipated and we currently expect to complete enrollment of all patients in the trial by the end of 2025,” said Dr. Tiago Reis Marques, Chief Executive Officer of Pasithea.
Neutral
GlobeNewsWire
1 month ago
Pasithea Therapeutics to Present Updated Data from Ongoing Phase 1 Trial of PAS-004 in Advanced Cancer Patients at the 2025 ASCO Annual Meeting
MIAMI, April 24, 2025 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor, for the treatment of neurofibromatosis type 1 (NF1) and other MAPK pathway driven indications, today announced the acceptance of an abstract for a poster prenstation at the Annual Meeting of the American Society for Clinical Oncology (ASCO) taking place May 30 – June 3, 2025, in Chicago, Illinois. The Company will present updated interim clinical data from its onging Phase 1 clinical trial of PAS-004 in patients with MAPK pathway driven advanced solid tumors.
Charts implemented using Lightweight Charts™